This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Stocks With Big Insider Buying

Synta Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

One stock in the health care complex whose insiders have snapped up a large amount of shares of is Synta Pharmaceuticals (SNTA), a biopharmaceutical firm focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Insiders are buying into strength here since this stock is up over 47% in the last three months.

Synta Pharmaceuticals has a market cap of $224.82 million and an enterprise value of $190.47 million. This stock trades at a price-to-sales of 27.36 and a price-to-book of 9.13. Its estimated growth rate for this year is -18.3%, and for next year it's pegged at 6.4%. This is a cash-rich company, with a total cash position on its balance sheet of $50.66 million and total debt of $16.8 million.

A director and beneficial owner just bought 1.1 million shares, or close to $5 million worth of stock, at $4.40 per share.

From a technical standpoint, SNTA is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock recently bounced off its 50-day at $4.21 and its now moving back above its 200-day of $4.50 a share. Shares of SNTA are also starting to enter a gap down zone between $5 and $4.26 a share.

If you're bullish SNTA, I would look to be a buyer of this stock if it can manage to close back above its 200-day moving average of $4.50 on solid volume. Look for volume that registers near or well above its three-month average action of 216,222 shares.

If we get that action, then this stock has a good chance to run back towards its nearest overhead resistance levels at $5.15 to $5.23 a share. I would then add to any long positions if those levels are taken out with volume. I would use a mental stop just below near-term support at $4.44, or the 50-day at $4.21 if you want to give it more room.

Synta is rated D- sell by TheStreet Ratings.

5 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs